EGFR and lung carcinoma: For example, only 60% of lung cancer patients with the p.L858R mutation in the epidermal growth factor receptor gene (EGFR) respond to gefitinib, although all of them are carriers of the exact same mutation in the target gene, indicating that other, yet unknown genetic aberrations may influence the effect of targeted drugs and that the disease course is still unpredictable to a great extent [44].